Delving into the Latest Updates on HBG gene modified autologous CD34+ hematopoietic stem cells(Guangzhou Ruifeng) with Synapse

Overview

Drug Type

Gene therapy, Hematopoietic stem cell therapy

Synonyms

Target

Action

stimulants

Mechanism

HBG gene stimulators

Therapeutic Areas

Active Indication

Inactive Indication-

Originator Organization

Active Organization

Inactive Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Transfusion-dependent Beta Thalassemia	Phase 1	China	Guangzhou Ruifeng Biological Technology Co., Ltd.Startup	15 Dec 2022

Login to view more data

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASH2024	Not Applicable	Transfusion-dependent Thalassemia	-	RM-001	tiocwosnxp(pqluiuavui) = No RM-001-related serious adverse event report. All of adverse events have been resolved. There were no deaths, discontinuations, or malignancies. oowhtruusd (avfsrwfdzm )	-	09 Dec 2024
ChiCTR2100052858 \| ChiCTR2300069244 \| ChiCTR2100053406 (EHA2024) Manual	Phase 1	Beta-Thalassemia	16	RM-001	(bhgqwyntgz) = xjbkgygszi gvezkaccbh (rhwngrtqer ) Met View more	Positive	14 May 2024
ASH2023	Not Applicable	Transfusion-dependent Beta Thalassemia	7	RM-001	(eetlfnixfi) = ktdayfdmnw aboybwwjqo (smvkwujdtv ) View more	-	11 Dec 2023
EHA2022	Not Applicable	Transfusion-dependent Thalassemia	2	RM-001	(jjckfcrgfq) = dxumcgqvjk lxkmruuris (ylzdvdqhyp )	Positive	12 May 2022